Lucentis

Novartis plans to file for new Lucentis indication in ROP
Novartis plans to file for new Lucentis indication in ROP
Pharmaceutical Business Review
Novartis
Lucentis
ROP
retinopathy of prematurity
Flag link:
Roche, Novartis' Italian heads risk trial for alleged market rigging: sources
Roche, Novartis' Italian heads risk trial for alleged market rigging: sources
Yahoo/Reuters
Roche
Novartis
Italy
Avastin
Lucentis
marketing manipulation
Flag link:
Lucentis biosimilar: Formycon eyes 2020 for US launch
Lucentis biosimilar: Formycon eyes 2020 for US launch
BioPharma Reporter
Lucentis
Formycon
Genentech/Roche
FYB201
Flag link:
3 Big Pharma Companies With the Best Pipelines
3 Big Pharma Companies With the Best Pipelines
Motley Fool
JNJ
Actelion
Darzalex
Novartis
Cosentyx
Jakavi
Lucentis
Tasigna
Roche
Venclexta
Tecentriq
emicizumab
Flag link:
Biotechs line up to tap growing ophthalmics market
Biotechs line up to tap growing ophthalmics market
BioPharma Dive
Ophthalmic Drugs Market
Ocular Therapeutix
Eylea
Restasis
Lucentis
Regeneron
Roche
Allergan
Flag link:
Ophthotech Plunges on Eye Drug Study Failure
Ophthotech Plunges on Eye Drug Study Failure
TheStreet.com
Ophthotech
clinical trials
Fovista
Lucentis
wet age-related macular degeneration
Flag link:
9 Drugs That Cost Medicare a Fortune
9 Drugs That Cost Medicare a Fortune
Motley Fool
Medicare
Lucentis
Eylea
Prolia
Treanda
Lexiscan
Yervoy
Privigen
Provenge
Soliris
Flag link:
Regeneron Eye Drug's Advantage Over Roche's Narrowed in Trial
Regeneron Eye Drug's Advantage Over Roche's Narrowed in Trial
Bloomberg
Regeneron
dry eye disease
Roche
Lucentis
Eylea
Flag link:
Lucentis more effective than lasers for reversing diabetes-induced blindness in new study
Lucentis more effective than lasers for reversing diabetes-induced blindness in new study
BioPharma Dive
Lucentis
PDR
proliferative diabetic retinopathy
Roche
Flag link:
The Next Blockbusters Could Be Balms For Aging Eyes
The Next Blockbusters Could Be Balms For Aging Eyes
Investors.com
age-related macular degeneration
Bayer
Regeneron
Ophthotech
Allergan
Novartis
Applied Genetic Technologies
Avalanche Biotechnologies
Roche
Lucentis
Eylea
Flag link:
Eylea erodes Lucentis, Avastin market share
Eylea erodes Lucentis, Avastin market share
Medical Marketing and Media
Eylea
Lucentis
Avastin
Regeneron
Roche/Genentech
Flag link:
Biosimilar of Novartis' eye drug Lucentis launched in India
Biosimilar of Novartis' eye drug Lucentis launched in India
Fierce Pharma
Novartis
India
Lucentis
biosimilars
Flag link:
Pfizer Buys Your Biosimilar Partner? How Pfenex’ Heartburn Was Quickly Relieved
Pfizer Buys Your Biosimilar Partner? How Pfenex’ Heartburn Was Quickly Relieved
Informabi
BIO2015
biosimilars
Pfenex
Pfizer
Hospira
Lucentis
PF582
Flag link:
Did Novartis try to sabotage Avastin ophthalmic trials?
Did Novartis try to sabotage Avastin ophthalmic trials?
BioPharma Dive
Novartis
Avastin
Roche
Lucentis
Flag link:
BMJ: Novartis tried to 'scupper' trials to protect Lucentis from cheap Avastin
BMJ: Novartis tried to 'scupper' trials to protect Lucentis from cheap Avastin
Fierce Pharma
Novartis
clinical trials
Roche
Avastin
Lucentis
Flag link:
Ohr Pharma's eye drug fails main goal in mid-stage study
Ohr Pharma's eye drug fails main goal in mid-stage study
Yahoo/Reuters
Ohr Pharmaceutical
OHR-102
Lucentis
wet age-related macular degeneration
Flag link:
UK doctors lobby for off-label Avastin use
UK doctors lobby for off-label Avastin use
Medical Marketing and Media
UK
Avastin
off-label
Lucentis
wet age-related macular degeneration
Roche
Novartis
Flag link:
Regeneron Beats Genentech In Rare Face Off Over Diabetes-Related Vision Loss
Regeneron Beats Genentech In Rare Face Off Over Diabetes-Related Vision Loss
Forbes
Regeneron
Genentech
diabetes
Eylea
Lucentis
DME
diabetic macular edema
Flag link:
Pharma Files Complaint Against Italy for Reimbursing Off-Label Prescribing
Pharma Files Complaint Against Italy for Reimbursing Off-Label Prescribing
WSJ Pharmalot
Italy
off-label
Avastin
Lucentis
Roche
Novartis
Flag link:
Roche's blockbuster Lucentis nabs fourth FDA approval
Roche's blockbuster Lucentis nabs fourth FDA approval
BioPharma Dive
Roche
Lucentis
FDA
DME
diabetic macular edema
Flag link:

Pages